Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD.

J Clin Oncol. 2006 Aug 1;24(22):3651-6.

PMID:
16877733
2.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups.; National Cancer Institute of Canada Clinical Trials Group..

N Engl J Med. 2005 Mar 10;352(10):987-96.

3.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS.

Neuro Oncol. 2004 Apr;6(2):134-44.

4.

Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ.

Cancer Res. 2003 Sep 15;63(18):5656-68. Review.

5.

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.

Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, Faivre S, Sicard E, Germa C, Rodier JM, Vernillet L, Armand JP.

Ann Oncol. 2003 Apr;14(4):603-14.

PMID:
12649109
6.

Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme.

Choi IS, Lee SH, Kim TY, Bang JS, Paek SH, Kim S, Kim IH, Heo DS, Bang YJ, Kim DG, Jung HW, Kim NK.

J Neurooncol. 2002 Nov;60(2):171-6.

PMID:
12635665
7.

A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.

Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL.

Neuro Oncol. 2002 Oct;4(4):261-7.

8.

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C.

Int J Cancer. 2002 Jul 1;100(1):43-8.

10.

Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study.

Viñolas N, Gil M, Verger E, Villá S, Pujol T, Ceral L, García M, Graus F.

Anticancer Drugs. 2002 Feb;13(2):163-7.

PMID:
11901309
11.

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R.

J Neurosurg. 2001 Aug;95(2):190-8.

PMID:
11780887
12.
13.

Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study.

Weller M, Streffer J, Wick W, Kortmann RD, Heiss E, Küker W, Meyermann R, Dichgans J, Bamberg M.

Cancer. 2001 Jan 15;91(2):423-7.

PMID:
11180090
14.

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.

Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH.

J Clin Oncol. 2000 Feb;18(4):927-41.

PMID:
10673536
15.

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Rowinsky EK, Windle JJ, Von Hoff DD.

J Clin Oncol. 1999 Nov;17(11):3631-52. Review.

PMID:
10550163
16.
17.

Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.

Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, Piantadosi S.

J Clin Oncol. 1997 Sep;15(9):3121-8.

PMID:
9294475
18.
19.

Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.

Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM.

Cancer Res. 1995 Nov 15;55(22):5310-4.

20.

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.

Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, et al.

Nat Med. 1995 Aug;1(8):792-7.

PMID:
7585182
Items per page

Supplemental Content

Support Center